What question did this study set out to answer?

This study aims to evaluate the anticancer efficacy and safety of doxorubicin-loaded nanoparticles administered orally in a breast cancer model.

May 10, 2011Molecular Pharmaceutics

Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model

Q: What is the clinical evidence from this study?

Study design: Other. Population: Breast cancer. Intervention: Orally administered doxorubicin-loaded PLGA nanoparticles (Dox-NPs) vs. Intravenously injected free doxorubicin. Primary outcome: Tumor growth suppression and cardiotoxicity.

View Full Paper

Ask AI

Bookmark

Key result

Orally administered doxorubicin-loaded PLGA nanoparticles significantly suppressed breast tumor growth and markedly reduced cardiotoxicity compared to intravenously injected free doxorubicin.

Why the study?

Does orally administered doxorubicin-loaded PLGA nanoparticles improve anticancer efficacy and reduce cardiotoxicity compared to intravenous free doxorubicin in a breast cancer animal model?

Population

Breast cancer induced animal model (female Sprague-Dawley rats) and C127I/Caco-2 cell lines

Comparison

Orally administered doxorubicin-loaded poly… vs Intravenously injected free doxorubicin

Design

Preclinical

Authors

AJAmit JainGuru Gobind Singh Medical College and Hospital NSNitin K. SwarnakarBASF (United States)MDManasmita DasUniversity of North Carolina at Chapel Hill

Discussion

Member takes

Implication

Oral Dox-NPs show preclinical efficacy in breast cancer models; hypothesis-generating and requires human trials before consideration.

Key Points

This study aims to evaluate the anticancer efficacy and safety of doxorubicin-loaded nanoparticles administered orally in a breast cancer model.
Utilized Dox-NPs prepared from PLGA with 55.40% entrapment efficiency and size of 160.20 nm.
Conducted cytotoxicity tests on C127I cell line and breast tumor suppression evaluation in female Sprague-Dawley rats.
Assessed cardiac safety markers including malondialdehyde, lactate dehydrogenase, and histopathological changes.
Dox-NPs exhibited higher cytotoxicity after 72 h compared to free Dox in C127I cells.
Significant growth suppression of breast tumors in rats treated with Dox-NPs.
Marked reduction in cardiotoxicity with orally administered Dox-NPs compared to intravenously injected free Dox.

Structured PICO

Does orally administered doxorubicin-loaded PLGA nanoparticles improve anticancer efficacy and reduce cardiotoxicity compared to intravenous free doxorubicin in a breast cancer animal model?

Population

Female Sprague-Dawley rats with induced breast tumors evaluated for anticancer efficacy and cardiotoxicity of oral doxorubicin nanoparticles.

Intervention

Orally administered doxorubicin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Dox-NPs)

Comparator

Intravenously injected free doxorubicin (and free Dox solution for in vitro assays)

Outcome

Anticancer efficacy (tumor growth suppression) and cardiotoxicity (MDA, LDH, CK-MB, GSH, SOD levels and histopathology)surrogate

Oral doxorubicin-loaded PLGA nanoparticles may offer a promising strategy to maintain anticancer efficacy while significantly reducing doxorubicin-induced cardiotoxicity.

Cite This Study

Jain et al. (2011) studied Breast cancer. Orally administered doxorubicin-loaded PLGA nanoparticles (Dox-NPs) vs. Intravenously injected free doxorubicin was evaluated on Tumor growth suppression and cardiotoxicity. Orally administered doxorubicin-loaded PLGA nanoparticles significantly suppressed breast tumor growth and markedly reduced cardiotoxicity compared to intravenously injected free doxorubicin.

synapsesocial.com/papers/6a635dfb95f5f7c18b6a91a2 https://doi.org/10.1021/mp200011f

View Full Paper

Ask AI

Bookmark

Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider